RemeGen Co. Ltd. Class H (HK:9995) has released an update.
RemeGen Co., Ltd. has announced adjustments to its previously proposed issuance plan, initially detailed in earlier announcements and circulars. The company’s board and supervisors, authorized by shareholders, have revised the plan to ensure it aligns with legal requirements, actual company circumstances, and the final investment decisions will be adjusted according to the actual net proceeds. This adjustment allows the company to flexibly manage the investment for the development of innovative drugs, with a cap of RMB2,550 million for the total proceeds, ensuring shareholder interests are safeguarded.
For further insights into HK:9995 stock, check out TipRanks’ Stock Analysis page.
